Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

6.300 -0.270 (-4.11%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
A Preview Of Amylyx Pharma's Earnings
Via Benzinga
Amylyx Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 10, 2023
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
3 Biotech Stocks to Buy Before Drug Trials End
Drug trials are a chance for high risk, high reward investing. These stocks doing neurodegenerative trials could be set for big gains. 
Via InvestorPlace
Why Shares of Amylyx Pharmaceuticals Were Up Monday
The company got a bump from an analyst's upgrade. 
Via The Motley Fool
4 Analysts Have This to Say About Amylyx Pharma
Via Benzinga
7 Analysts Have This to Say About Amylyx Pharma
Via Benzinga
What 7 Analyst Ratings Have To Say About Amylyx Pharma
Via Benzinga
Amylyx Stock Has A Good Entry Point, Says Bullish Goldman Sachs
Shares of Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) jumped in early trading on Monday, after remaining broadly flat last week. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023
Via Benzinga
Amylyx Pharmaceuticals to Host Virtual Webcast on AMX0035 Progressive Supranuclear Palsy (PSP) Program
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Analyst Expectations for Amylyx Pharma's Future
Via Benzinga
Amylyx Pharma Earnings Preview
Via Benzinga
EMA's Advisory Panel Gives Thumbs Down To Amylyx Pharma's Amyotrophic Lateral Sclerosis Treatment
The European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a negative opinion regarding Amylyx Pharmaceuticals Inc's (NASDAQ: AMLX) conditional marketing authorization... 
Via Benzinga
Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Completes Negotiation Process and Signs Letter of Intent with the pCPA for ALBRIOZA™ for the Treatment of ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Better Growth Stock: Amylyx Pharmaceuticals or Viking Therapeutics?
Which of these red-hot biotech stocks is the better buy right now? 
Via The Motley Fool
Amylyx Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run
Shares surged into and out of the company's R&D Day, which included a surprise. 
Via Investor's Business Daily
Amylyx Pharmaceuticals Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European Union
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Turns Profitable On Successful Drug Launch
Amylyx Pharmaceuticals is the rare young biotech that's profitable. The company earned $0.02 a share in Q1, and analysts expect profitability to grow. 
Via MarketBeat
2 Supercharged Growth Stocks to Buy Right Now
These two biopharma stocks might be poised for a major breakout. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
US Stock Futures Signal Strong Finish To Wobbly Week — But Analyst Still Sees Recession Risk On Horizon
Via Benzinga
Amylyx Blows Past Sales Expectations, Reports Unexpected Profit — Shares Rocket
The company was expected to post another loss, but instead came in with a gain of 2 cents per share. 
Via Investor's Business Daily
Amylyx Pharmaceuticals Reports First Quarter 2023 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
3 Biotechs That Might Get Bought Out in 2023
Biotech is expected to be a hotbed of mergers and acquisitions this year. 
Via The Motley Fool
Amylyx Pharmaceuticals Appoints Masako Nakamura to General Manager and Head of International Markets - Asia Pacific and Latin America
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS